Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,758 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05080556RecruitingPhase 2
Adaptive chemotherapy for ovarian cancer after platinum and PARP
This trial tests a personalized (adaptive) chemotherapy plan for people with certain types of ovarian/fallopian tube/peritoneal cancer who already had platinum chemotherapy and a PARP inhibitor. It’s for patients whose cancer came back after (or still responds to) prior platinum treatment and may help delay disease progression.
LondonAges 18 years+ - NCT06376721RecruitingPhase 1/Phase 2
Linperlisib combo for advanced NK/T-cell lymphoma
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT05727605Recruiting
Thinking changes after radiotherapy for brain and skull-base tumors
This trial studies how radiotherapy affects memory and thinking in adults with certain brain or skull-base tumors. It may help doctors understand who is most likely to have thinking changes and how to monitor or support patients.
GhentAges 18 years+ - NCT06124287Recruiting
Can MRI predict Crohn's relapse after stopping biologics?
This study looks at whether MRI scans can predict when Crohn's disease will come back after stopping biologic medications. If you are in remission and recently stopped a biologic, researchers want to see if your MRI results can help understand your risk of relapse.
LondonAges 16 years+ - NCT06421298RecruitingPhase 2
Tafolecimab and sintilimab plus chemo for advanced lung cancer
This trial is testing a new combination of treatments, including an immune drug (sintilimab) and a cholesterol-lowering drug (tafolecimab), along with chemotherapy, for people with advanced lung cancer that no longer responds to standard immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT07851636Recruiting
Fast genetic testing to guide treatment for rare brain tumors
This trial tests a new way to pick treatments for rare brain tumors that have come back. Doctors will quickly analyze your tumor's genes and test drugs in the lab to find the best option for you.
Washington D.C., District of ColumbiaAges Up to 45 years - NCT05536089Recruiting
Testing blood methylation to predict colorectal cancer relapse
This trial checks a blood test for “ctDNA methylation” to see who may be at higher risk of colorectal cancer returning after surgery. It may help doctors better judge whether adjuvant chemotherapy is working or needed.
Hangzhou, ZhejiangAges 18 years+ - NCT04625907RecruitingPhase 1/Phase 2
Study testing treatment options for children and adults with RMS
This study tests different treatment approaches for rhabdomyosarcoma (RMS) in children and adults, including newly diagnosed high-risk cases, people needing radiotherapy, and people whose RMS has returned. It’s designed to find safer dosing and more effective therapy while checking whether participants can proceed based on health and timing requirements.
BrisbaneAges Any age - NCT07826689RecruitingPhase 1/Phase 2
Oral pill for relapsing multiple sclerosis
This study tests an experimental oral drug, PRO-1562, in two parts: first in healthy volunteers to check safety, then in people with relapsing multiple sclerosis to see if it can reduce disease activity. It may offer a new, convenient treatment option.
Adelaide, South AustraliaAges 18–65 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT06497387RecruitingEarly Phase 1
PRG-1801 for stubborn lupus kidney and IgG4 disease
This trial tests a new treatment called PRG-1801 for people with lupus nephritis (kidney inflammation from lupus) or IgG4-related disease that has not improved with standard treatments. The treatment uses your own immune cells to target and calm the disease.
Wuhan, HubeiAges 18 years+ - NCT06497361RecruitingEarly Phase 1
PRG-2311 for hard-to-treat lupus nephritis and IgG4 disease
This trial tests a new treatment called PRG-2311 for people with lupus nephritis or IgG4-related disease that has not responded to standard therapies. The treatment uses a type of immune cell therapy (CAR-T) to try to control the disease.
Wuhan, HubeiAges 18 years+ - NCT06508216RecruitingPhase 1/Phase 2
New drug combo for early relapsed triple-negative breast cancer
This trial tests experimental drugs for people with triple-negative breast cancer that came back within 12 months of finishing initial treatment. The goal is to see if these drugs are safe and can shrink or slow the cancer.
VillejuifAges 18 years+ - NCT07793500RecruitingEarly Phase 1
Nebulized drug for lung metastases from solid tumors
This study tests a new drug given as a mist you breathe in, for people whose cancer has spread to the lungs. The goal is to see if it can shrink tumors or slow their growth.
BeijingAges 18–75 - NCT06393816RecruitingPhase 2
Durvalumab plus chemotherapy for advanced LCNEC lung cancer
This trial tests a combination of the immunotherapy drug durvalumab (Imfinzi) with standard chemotherapy (etoposide and a platinum drug) as a first treatment for advanced large-cell neuroendocrine carcinoma of the lung. The goal is to see if this combination works better than chemotherapy alone.
Aix-en-ProvenceAges 18 years+ - NCT06125405RecruitingPhase 3
Telitacicept for children with frequently relapsing nephrotic syndrome
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
Hangzhou, ZhejiangAges 2–18 - NCT07774533RecruitingEarly Phase 1
Imaging osteosarcoma with a new PET tracer
This trial tests a new PET imaging tracer that may help see osteosarcoma tumors more clearly. It is for people whose osteosarcoma has not improved or has returned after standard treatment.
Beijing, Beijing MunicipalityAges 10–80 - NCT07774520RecruitingPhase 2
Lower dose of lazertinib plus magnesium to prevent nerve damage in advanced lung cancer
This trial tests a lower starting dose of the targeted therapy drug lazertinib combined with magnesium supplements to prevent a common side effect (peripheral neuropathy) in people with advanced lung cancer caused by certain EGFR mutations. The goal is to see if this approach keeps the drug effective while reducing nerve damage symptoms like numbness or tingling.
Seoul, Gang-nam GuAges 19 years+ - NCT04056533RecruitingPhase 2
Preventing CMV after a haploidentical stem cell transplant
This Phase 2 study tests a preventive “cell therapy” made from a donor’s immune cells to lower the risk of CMV infection after a haploidentical stem cell transplant. If you’re at risk for CMV, this may help protect you during the early post-transplant period.
SantanderAges 18–80 - NCT07758270Recruiting
Brain scan study for multiple sclerosis treatment switch
This study looks at how a new pill for multiple sclerosis (MS) affects brain inflammation and immune cells. It may help people who are already taking an MS medication but want to switch to a different one.
St Louis, MissouriAges 40–70 - NCT07734493RecruitingPhase 1
Study of a new drug for acute schizophrenia symptoms
This trial tests an experimental medicine, LTX-001, for people with schizophrenia who are currently having a sudden worsening of symptoms. It aims to see if the drug can help reduce these acute symptoms.
Little Rock, ArkansasAges 18–55 - NCT07714512RecruitingPhase 1/Phase 2
Anti-CD38 antibody for severe aplastic anemia not helped by other treatments
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT06654154Recruiting
Vitamin B12 as a marker for disease activity in tocilizumab patients
This study looks at whether vitamin B12 levels in the blood can help tell if your disease is active or if you have an infection while being treated with tocilizumab. The goal is to find a simple way to monitor your condition without extra invasive tests.
Clermont-FerrandAges 18 years+
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,758 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.